Gaois

Cóip statach de shonraí a easpórtáiltear ó IATE ó am go chéile atá sa chnuasach seo. Níor cheart glacadh leis gurb ionann i gcónaí an t-eolas a thugtar faoi iontráil anseo agus a bhfuil sa leagan reatha den iontráil ar IATE. Is féidir an leagan reatha sin a cheadú ach cliceáil ar an nasc atá ar thaobh na láimhe deise ag barr gach iontrála. Breis eolais »

3 thoradh

  1. PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology · SOCIAL QUESTIONS|health|pharmaceutical industry · SOCIAL QUESTIONS|health|illness|cancer

    #684942

    IATE #3578242
    T-chill gabhdóra chiméaraigh aintaiginí Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    chimeric antigen receptor T cell | CAR T cell | CAR-T cell
    en
    Sainmhíniú "T-lymphocyte which is genetically modified by adding a gene expressing a special receptor (called a chimeric antigen receptor) through which it is targeted against surface components of tumour cells in order to kill those cells" Tagairt "COM-Terminology Coordination, based on:Kieran Breen. 'Chimeric antigen receptor (CAR) T cell therapies' (30.4.2024). European Medicines Agency (EMA)"
  2. PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology · SOCIAL QUESTIONS|health|pharmaceutical industry · SOCIAL QUESTIONS|health|illness|cancer

    #684940

    IATE #3578239
    gabhdóir ciméarach aintaiginí Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    chimeric antigen receptor | CAR
    en
    Sainmhíniú "specially engineered receptor, i.e. created in the laboratory, that is designed to bind to certain proteins on cancer cells" Tagairt "COM-Terminology Coordination, based on: 'chimeric antigen receptor' (30.4.2024). NCI Dictionary of Cancer Terms. National Cancer Institute"
  3. SOCIAL QUESTIONS|health|medical science

    #684941

    IATE #3578241
    teiripe T-cheall le gabhdóir ciméarach aintaiginí Tagairt "Faofa ag an gCoiste Téarmaíochta, www.tearma.ie ;Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    chimeric antigen receptor T cell therapy | CAR T cell therapy | CAR-T cell therapy | CAR-Tcell therapy
    en
    Sainmhíniú "type of treatment with CAR T-cells derived from a patient’s own blood (autologous) or derived from a healthy person (allogenic) which are grown in large numbers in the laboratory and then given to the patient by infusion" Tagairt "COM-Terminology Coordination, based on:Kieran Breen, Chimeric antigen receptor (CAR) T cell therapies (1.2.2021), European Medicines Agency (EMA)"
    Nóta Memorial Sloan Kettering Cancer Center (MSK) announced on 14.9.2023 that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences. The prestigious prize recognizes Dr. Sadelain and Carl June, MD, of the University of Pennsylvania, for the development of chimeric antigen receptor T cell immunotherapy (CAR T cell therapy) whereby the patient’s T cells are modified to target and kill cancer cells. Dr. Sadelain is a pioneer and leader in the field of immunology, genetic engineering, and the development of CAR T cell therapy. A type of immunotherapy, CAR T cell therapy uses genetically engineered versions of a person’s own immune cells to find and fight cancer.